Humacyte (NASDAQ:HUMA) Given Buy Rating at HC Wainwright

by · The Cerbat Gem

HC Wainwright reissued their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research report report published on Friday, Marketbeat Ratings reports. HC Wainwright currently has a $15.00 target price on the stock, up from their prior target price of $12.00.

Several other research firms have also commented on HUMA. Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. Piper Sandler set a $6.00 target price on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Thursday, November 21st. BTIG Research reiterated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $13.43.

Read Our Latest Research Report on Humacyte

Humacyte Price Performance

Humacyte stock opened at $4.64 on Friday. Humacyte has a 52-week low of $2.48 and a 52-week high of $9.97. The company has a market cap of $583.99 million, a price-to-earnings ratio of -3.46 and a beta of 1.38. The firm’s fifty day moving average is $4.83 and its 200 day moving average is $5.85. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insider Transactions at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. The trade was a 13.12 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,500,000 shares of company stock worth $6,606,799. 11.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Humacyte

Institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in Humacyte in the second quarter worth about $28,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte in the 3rd quarter valued at about $75,000. Principal Financial Group Inc. purchased a new stake in shares of Humacyte in the 2nd quarter worth approximately $83,000. FORA Capital LLC bought a new position in shares of Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC purchased a new position in Humacyte during the second quarter valued at approximately $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Featured Stories